Immunotherapy for Genitourinary Cancers: New Opportunities for Clinical Impact

It would be an understatement to say that the concept of immunotherapy —the treatment of cancer through suppression or stimulation of the immune system—was slow to gain acceptance. A century passed between the publication of William B. Coley’s report of a treatment for sarcoma employing “bacterial toxins” and the first Food and Drug Administration–approved immunotherapy in 1990, bacillus Calmette-Guérin (BCG) for bladder cancer. In the 30 years since, immunotherapy has revolutionized cancer treatment.
Source: Urologic Clinics of North America - Category: Urology & Nephrology Authors: Tags: Preface Source Type: research